Compare TPH & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPH | SUPN |
|---|---|---|
| Founded | 2009 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | N/A | 2012 |
| Metric | TPH | SUPN |
|---|---|---|
| Price | $33.66 | $48.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $41.40 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 763.1K | 634.0K |
| Earning Date | 02-25-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.42 | N/A |
| Revenue | ★ $3,751,941,000.00 | $681,539,000.00 |
| Revenue This Year | N/A | $8.16 |
| Revenue Next Year | N/A | $23.82 |
| P/E Ratio | $9.73 | ★ N/A |
| Revenue Growth | N/A | ★ 4.54 |
| 52 Week Low | $27.90 | $29.16 |
| 52 Week High | $38.73 | $57.65 |
| Indicator | TPH | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 50.12 | 44.83 |
| Support Level | $34.05 | $47.94 |
| Resistance Level | $34.17 | $50.09 |
| Average True Range (ATR) | 1.09 | 1.55 |
| MACD | -0.16 | -0.29 |
| Stochastic Oscillator | 22.29 | 20.39 |
Tri Pointe Homes Inc is an American construction company that focuses on residential construction. The company is engaged in the design, construction, and sale of single-family attached and detached homes in different states across the United States. Its operations are organized into two principal businesses: homebuilding. which generates key revenue, and financial services. The homebuilding business has three reportable operating segments, based on the geographical layout of the markets, and includes West region, Central region, and East region. The company's financial services operation is comprised of its Tri Pointe Connect mortgage financing operations, Tri Pointe Assurance title and escrow services operations, and Tri Pointe Advantage property and casualty insurance agency operations.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.